Medannex are urgently seeking partners to help expedite the development of a novel antibody (MDX-124) which may help in the fight against COVID-19.

MDX-124 targets annexin-A1, a key component of the immune system. Annexin-A1 facilitates multiple steps in the lifecycle of viruses, together with their incorporation and proliferation in human cells – which is of particular importance in the current pandemic. By blocking annexin-A1, our antibody could disrupt the infectivity and transmission of SARS-CoV-2 and lessen the impact of the associated cytokine storm.

Medannex are in need of a non-insulin dependent MCF-7 breast cancer cell line.

Download a one-page summary on the role of MDX-124 in this setting below.

Medannex is looking for ‘plug and play’ in vitro assays for testing our humanised antibody to annexin-A1 in the context of COVID-19 (possibly followed by in vivo).

If you think you may be able to help Medannex, contact us through the button below or send an e-mail to